Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. Hospices Civils de Lyon, Lyon, France



Survival: 12.1 months
   
Toxicity Grade: 5
   
Treatments: Chemotherapy
   
Drugs:
Country: France
   
City/State/Province: Lyon
   
Hospital: Hospices Civils de Lyon
   
Journal: Link
   
Date: 10/2012

Description:
Patients:
This phase 3 study involved patients with advanced non-small-cell lung cancer patients, previously treated with cisplatin and gemcitabine, who were divided into two treatment groups. Group A consisted of 154 patients with a median age of 57.9 years and 73.4% male. Group B had 155 patients with a median age of 56.4 years and 72.9% male.

Treatment:
Patients in group A were treated with the chemotherapy agent gemcitabine.

Patients in group B were treated with the biologic therapy agent erlotinib, which blocks tumor cell growth by inhibiting a protein called EGFR.

Toxicities:
There were two treatment-related deaths in group A due to pneumonia and kidney failure. Grade 3-4 neutropenia, thrombocytopenia, and anemia were also reported.

The most severe toxicities in group B were of grade 4. Grade 3-4 toxicities included rash, infection, and pneumonia.

Results:
The median overall survival was 12.1 months for group A and 11.4 months for group B.

Support:
This study was partially supported by the pharmaceutical companies Roche and Eli Lilly.

Correspondence: Dr. Maurice Perol; email: maurice.perol@lyon.unicancer.fr

E-mail to a Friend Email Physician More Information